Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 43 positions · Total reported value $3.92B · Top-10 concentration 72.7% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 28.3% · 5 new · 5 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -16.2% · vs SPY -18.3% · Prev Value $4.59B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.4% · vs SPY -4.5% · Latest Value $3.92B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Frazier Life Sciences Management, L.P. disclosed 43 equity positions with a combined reported value of $3.92B. The filing implies a focused portfolio: its ten largest positions account for 72.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were MIRM ($656.46M), NAMS ($461.81M), ERAS ($432.11M). By sector, the heaviest allocations are Health Care 99.7%, Materials 0.2%.

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 5 new positions, trimmed 5 and fully exited 3, a turnover rate of 28.3% of positions. The portfolio's overlap with the prior quarter was 83% of names.

The largest new positions opened in Q3 2026 were ATOS ($120.77M), CLDX ($29.17M), SRPT ($19.49M).

Of the 3 positions fully exited versus the prior quarter, the largest were BBIO ($115.31M), CYTK ($98.81M), ALKS ($36.71M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ATOS ATOSSA THERAPEUTICS INC · $120.77M
  • CLDX CELLDEX THERAPEUTICS INC NEW · $29.17M
  • SRPT SAREPTA THERAPEUTICS INC · $19.49M
  • ORIC ORIC PHARMACEUTICALS INC · $10.13M
  • TLGYF TCGX ACQUISITION CORP · $3.75M

Fully Exited (vs previous quarter)

  • BBIO BRIDGEBIO PHARMA INC · prev qtr: $115.31M
  • CYTK CYTOKINETICS INC · prev qtr: $98.81M
  • ALKS ALKERMES PLC · prev qtr: $36.71M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q3 2026 it reported 43 US equity positions with a combined value of $3.92B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 43 positions · $3.92B reported value (Q3 2026)
  • Top 10 holdings = 72.7% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 16.7%
  • Average position size: $91.26M

Sector Tilt

  • Health Care 99.7%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 5 new, 10 added, 5 reduced, 3 exited
  • 23 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively increasing exposure to select biotech/healthcare names (adds > reduces), suggesting a bullish view on specific therapeutic areas, while trimming some positions (e.g., KRYS, TRVI) to rebalance weights. 2. Key moves: - Added: NAMS (+5% shares), ERAS (+18% shares), MAZE (+5% shares). - Reduced: TRVI (-4% shares), KRYS (-18.7% shares). - New: ATOS (initial position). - Held: MIRM, MBX, ARQT, PVLA (no share changes). 3. Portfolio structure: Active, concentrated (43 positions), heavily biased toward Health Care (biopharma/therapeutics). Moderate risk appetite—mix of established (MIRM) and high-growth (ERAS, ATOS) names. 4. Per-holding one-liner: - MIRM: MIRUM PHARMACEUTICALS (rare disease therapeutics) - NAMS: NEWAMSTERDAM PHARMA (pain management) - ERAS: ERASCA INC (cancer therapeutics) - MBX: MBX BIOSCIENCES (gene editing) - ARQT: ARCUTIS BIOTHERAPEUTICS (dermatology) - MAZE: MAZE THERAPEUTICS (genetic medicines) - TRVI: TREVI THERAPEUTICS (kidney disease) - KRYS: KRYSTAL BIOTECH (rare skin disorders) - PVLA: PALVELLA THERAPEUTICS (genetic hearing loss) - ATOS: ATOSSA THERAPEUTICS (breast cancer) 5. Style summary: Biotech-focused fund tactically increasing positions in high-potential therapeutics while trimming laggards, maintaining a concentrated, high-conviction portfolio.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:48

Sector Allocation

Health Care 99.7%
Materials 0.2%
Other 0.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 7.68M $656.46M 16.73%
16.73%
Hold
2 18.99M $461.81M 11.77%
11.77%
Add
3 29.48M $432.11M 11.01%
11.01%
Add
4 6.65M $389.94M 9.94%
9.94%
Hold
5 9.87M $260.98M 6.65%
6.65%
Hold
6 5.28M $143.59M 3.66%
3.66%
Add
7 9.54M $136.60M 3.48%
3.48%
Reduce
8 391.32K $130.14M 3.32%
3.32%
Reduce
9 882.40K $121.71M 3.10%
3.10%
Hold
10 7.05M $120.77M 3.08%
3.08%
New
11 12.47M $91.01M 2.32%
2.32%
Hold
12 2.33M $75.26M 1.92%
1.92%
Add
13 3.85M $62.07M 1.58%
1.58%
Add
14 7.61M $61.60M 1.57%
1.57%
Hold
15 15.76M $61.45M 1.57%
1.57%
Add
16 934.85K $61.20M 1.56%
1.56%
Reduce
17 720.34K $56.63M 1.44%
1.44%
Reduce
18 2.74M $52.35M 1.33%
1.33%
Add
19 225.16K $51.30M 1.31%
1.31%
Hold
20 1.90M $50.11M 1.28%
1.28%
Hold
21 8.73M $45.92M 1.17%
1.17%
Add
22 7.10M $44.59M 1.14%
1.14%
Hold
23 22.45M $35.91M 0.92%
0.92%
Hold
24 4.01M $33.40M 0.85%
0.85%
Hold
25 900.08K $29.17M 0.74%
0.74%
New
26 1.44M $28.98M 0.74%
0.74%
Hold
27 3.75M $25.57M 0.65%
0.65%
Hold
28 829.75K $25.13M 0.64%
0.64%
Add
29 1.81M $22.75M 0.58%
0.58%
Hold
30 2.63M $21.05M 0.54%
0.54%
Hold
31 1.07M $19.49M 0.50%
0.50%
New
32 1.02M $18.33M 0.47%
0.47%
Hold
33 4.82M $16.31M 0.42%
0.42%
Hold
34 2.29M $14.17M 0.36%
0.36%
Hold
35 1.20M $13.70M 0.35%
0.35%
Add
36 1.00M $11.93M 0.30%
0.30%
Hold
37 751.67K $10.13M 0.26%
0.26%
New
38 4.45M $8.63M 0.22%
0.22%
Hold
39 500.33K $6.33M 0.16%
0.16%
Hold
40 1.11M $5.75M 0.15%
0.15%
Reduce
41 422.50K $3.82M 0.10%
0.10%
Hold
42 300.00K $3.75M 0.10%
0.10%
New
43 1.95M $2.31M 0.06%
0.06%
Hold

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2026-Q3?

In its 2026-Q3 13F filing, Frazier Life Sciences Management, L.P. reported 43 equity positions worth $3.92B in aggregate; its largest disclosed positions were MIRM ($656.46M), NAMS ($461.81M), ERAS ($432.11M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $3.92B of long equity holdings across 43 positions as of 2026-Q3. Top-10 holdings account for 72.7% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →